SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses potential price movements and upcoming catalysts, like a possible Solana ETF. Community members are focused on phrases like "WAGMI" and speculate on $200+ targets. There's also discussion around various Solana-based meme coins gaining traction.

Pump.fun

$PUMP is trending amid community enthusiasm and the popular 'WAGMI' (We're All Gonna Make It) mantra, with many highlighting its potential within the Solana ecosystem. Discussions revolve around its strong community, recognizable branding, and the belief that it's coded for significant growth. The community views $PUMP as more than just a ticker, but a mission statement.

Trump For President

The Trump Crypto token is trending amidst community discussions around its performance and potential connection to political events. Some traders are expressing concerns about its volatility, while others are speculating on future growth tied to Trump's political activity; overall sentiment appears mixed, with some users calling it a 'scam coin'.

WorldFinancial

WLFI is trending as community members discuss its connection to $TRUMP and potential for real-world asset tokenization. Speculation is fueled by potential partnerships and product launches like the USD1 stablecoin and a debit card. Community chatter also focuses on market manipulation, short squeezes, and the impact of regulatory clarity.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid rumors of a potential acquisition by Novartis, driving significant community discussion and a surge in stock price. Investors are closely watching upcoming conferences and data readouts, speculating on the likelihood of a buyout offer and its potential premium. The focus remains on Avidity's pipeline and its potential impact on the rare neuromuscular disease treatment landscape.

Shibmas was launched on the 9th Of December. The project is a meme token and gives homage to Shiba Inu the token. The token is a playful character who is bringing the Christmas spirit to token holders all around the world. We plan on getting many listings on various exchanges in the coming days. We have over 1000 holders in 24 hours and we aim on getting over 10000 holders within the next week and in the run up to Christmas

Shibmas

Shibmas ($SMAS) is gaining attention, with community members noting its trending status and "moon vibes." Talk centers on its availability on Phantom Wallet and potential breakout, as well as its connection to the Shiba Inu ($SHIB) community. Traders are closely watching price action and volume for signals.

Mid-America Apartment Communities, Inc. is a real estate investment trust, which engages in the operation, acquisition, and development of apartment communities. It operates through the Same Store and Non-Same Store segments. The Same Store Communities segment represents those apartment communities that have been owned and stabilized for at least 12 months as of the first day of the calendar year. The Non-Same Store segment includes recent acquisitions, communities in development or lease-up. The company was founded in 1994 and is headquartered in Germantown, TN.

Mid-America Apartment Communities, Inc.

Mid-America Apartment Communities ($MAA) is trending amid rating updates from analysts, with community members actively discussing target prices and potential ROI on call options. Discussions also highlight multifamily REIT resilience and the impact of interest rate fluctuations. Some are weighing the company's Sunbelt exposure against concerns about rental supply and rising interest expenses.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction in its long-term potential within the Solana ecosystem. Discussions highlight its resilient market capitalization, growing holder base, and potential for significant revaluation as part of the cultural finance movement on Solana. The community emphasizes that "We're All Gonna Make It" is more than just a meme, but a core principle.

Performance Food Group Co. engages in the market and distribution of food products. It operates through the following segments: Foodservice, Convenience, and Specialty. The Foodservice segment delivers food and food-related products to independent restaurants, chain restaurants, and other institutional food-away-from-home locations. The Convenience segment consists of a range of products, marketing programs and technology solutions to locations in the United States and Canada. The Specialty segment offers candy, snack, and beverage to customers in the vending, office coffee services, theater, retail, and other channels. The company was founded by James Capers in 1885 and is headquartered in Richmond, VA.

Performance Food Group Company

Performance Food Group is trending due to reports of takeover interest from US Foods, sparking community discussion about a potential deal. Upgraded ratings from analysts at Barclays and Bernstein, along with call option alerts, are also contributing to the increased attention. Investors are also reviewing the company's recent earnings, which beat expectations, and 10-K risk factors.

Fidelity National Financial, Inc. engages in the provision of title insurance and transaction services to the real estate and mortgage industries. Its services include title insurance, escrow and other title-related services, including trust activities, trustee sales guarantees, recordings and reconveyances, and home warranty products and technology and transaction services to the real estate and mortgage industries. The company operates through the following segments: Title, F&G, and Corporate and Other. The Title segment consists of the operations of title insurance underwriters and related businesses. The F&G segment consists of operations of annuities and life insurance related businesses. The Corporate and Other segment is involved in real estate brokerage businesses. Fidelity National Financial was founded by William P. Foley II in 1984 and is headquartered in Jacksonville, FL.

Fidelity National Financial Inc

FNF is trending as investors discuss its upcoming Q3 earnings and recent news, including insider trading activity. Community members are also weighing in on the company's dividend yield and overall dependence on real estate transaction volume. Some see it as a long term hold, while others anticipate potential price swings in the short term.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline

Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.

Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.

Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?

Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.

AbbVie Up More Than 30% in 6 Months: How to Play the Stock

AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.

The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies

Zacks spotlights AstraZeneca, RTX, and Applied Materials for strong performance and growth potential, while microcap names Park Aerospace and NetSol Technologies show niche momentum.

Top Research Reports for AstraZeneca, RTX & Applied Materials

AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

<p>AstraZeneca&nbsp;drew some retail investor attention early Monday after the pharma major reported that its cancer therapy Enhertu, developed with Daiichi Sankyo, achieved the highest pathologic complete response rate ever seen in a Phase 3 study for HER2-positive early breast cancer, showing both superior efficacy and a favorable safety profile compared with standard treatment.</p><h2 class="st-heading-2"><strong>Trial Results Show Record Response Rates</strong></h2><p>The DESTINY-Breast11 study, presented at the ESMO 2025 Presidential Symposium in Berlin, found that Enhertu followed by paclitaxel, trastuzumab and pertuzumab (THP) led to a pathologic complete response rate of 67.3%, compared with 56.3% for the standard anthracycline-based regimen (ddAC-THP). That marks an 11.2% absolute improvement, seen across both hormone receptor–positive and negative patients.</p><p>After surgery, over 81% of patients in the Enhertu group had no or minimal residual invasive cancer compared to 69% of patients treated with standard therapy. An early analysis of event-free survival showed a favorable trend with Enhertu, but the data are not mature.</p><h2 class="st-heading-2"><strong>Doctors See Potential New Standard Of Care</strong></h2><p>Nadia Harbeck, Director of the Breast Center at LMU University Hospital in Munich and the trial’s lead investigator, said the results suggest Enhertu could become a new standard of care in early, high-risk HER2-positive breast cancer.&nbsp;</p><p>AstraZeneca’s head of oncology R&amp;D Susan Galbraith added that the data show Enhertu “has the potential to transform treatment in the neoadjuvant setting.”</p><h2 class="st-heading-2"><strong>Safety Profile And Regulatory Outlook</strong></h2><p>Enhertu followed by THP was also better tolerated, with fewer severe side effects compared with standard therapy. Rates of Grade 3 or higher adverse events were 37.5% versus 55.8%, and heart-related side effects were lower. Interstitial lung disease rates were low and consistent across both groups.</p><p>The FDA is reviewing a supplemental Biologics License Application for Enhertu in this setting. Enhertu is being developed by AstraZeneca and Japan's Daiichi Sankyo.</p><h2 class="st-heading-2"><strong>Stocktwits Traders Turn Cautious</strong></h2><p>On Stocktwits, retail sentiment for AstraZeneca was ‘bearish’ amid ‘low’ message volume.</p><p><a href="https://stocktwits.com/symbol/AZN">AstraZeneca’s stock</a> has risen 32% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer

The Phase 3 trial showed Enhertu achieved a 67.3% complete response rate.

Equity

The Phase 3 trial showed Enhertu achieved a 67.3% complete response rate, outperforming standard therapy by more than 11 percentage points in high-risk HER2-positive early breast cancer.

DATROWAY (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option

Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual...

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc - ADR

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

AZN
AstraZeneca PLC

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AZN News

AZNAstraZeneca PLC